Cell-free DNA from ascites and pleural effusions: Molecular insights into genomic aberrations and disease biology

Molecular Cancer Therapeutics

Volumn 16, Issue 5, 2017, Pages 948-955

  Husain, Hatim ^a   Nykin, David ^a   Bui, Nam ^a   Quan, Daniel ^a   Gomez, German ^a   Woodward, Brian ^a   Venkatapathy, Sumathi ^b   Duttagupta, Radha ^b   Fung, Eric ^b   Lippman, Scott M ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Thermo Fisher Scientific   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL FREE DNA; CYCLIN DEPENDENT KINASE 4; DNA; DNA FRAGMENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EVEROLIMUS; PHOSPHATIDYLINOSITOL 3 KINASE; UNCLASSIFIED DRUG; CDK4 PROTEIN, HUMAN; CELL FREE NUCLEIC ACID; EGFR PROTEIN, HUMAN; MDM2 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN MDM2;

ADULT; AGED; ARTICLE; ASCITES; CANCER CYTODIAGNOSIS; CANCER PATIENT; CASE REPORT; CELL FREE SYSTEM; COPY NUMBER VARIATION; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN CELL; LUNG CANCER; MALE; METASTATIC BREAST CANCER; MIDDLE AGED; PLEURA EFFUSION; PRIORITY JOURNAL; SMOKING; TUMOR BIOPSY; TUMOR REGRESSION; VERY ELDERLY; BLOOD; CLASSIFICATION; GENETICS; HUMAN GENOME; MUTATION; NEOPLASM; PATHOLOGY; TUMOR CELL LINE;

ADULT; AGED; AGED, 80 AND OVER; ASCITES; CELL LINE, TUMOR; CELL-FREE NUCLEIC ACIDS; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; CYCLIN-DEPENDENT KINASE 4; DNA COPY NUMBER VARIATIONS; FEMALE; GENOME, HUMAN; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASMS; PLEURAL EFFUSION; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 85020053681     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-16-0436     Document Type: Article

References (18)

1. Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Vogelstein B, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012;486:537-40.
2. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intra-tumor heterogeneity and branched evolution revealed bymultiregion sequencing. N Engl J Med 2012;366:883-92.
3. Yang Y, Cottman M, Schiffman JD. Molecular inversion probes: a novel microarray technology and its application in cancer research. Cancer Genet 2012;205:341-55.
4. Wang Y, Carlton VE, Karlin-Neumann G, Sapolsky R, Zhang L, Faham M, et al. High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays. BMC Med Genomics 2009;2:8.
5. Lo YM, Chan KC, Sun H, Chen EZ, Jiang P, Chiu RW, et al. Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci Trans Med 2010;2:61ra91.
6. Fan HC, Blumenfeld YJ, Chitkara U, Hudgins L, Quake SR. Analysis of the size distributions of fetal and maternal cell-free DNA by paired-end sequencing. Clin Chem 2010;56:1279.
7. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 2013; 10:472-84.
8. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Diaz LA Jr, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014;6:224ra24.
9. Haber DA, Velculescu VE. Blood-based analyses of cancer: cell-free cells and cell-free DNA. Cancer Discov 2014;4:650-61.
10. Hirsch FR, Varella-Garcia M, McCoy J, West H, Xavier AC, Southwest Oncology Group, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 2005;23:6838-45.
11. Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012; 13:33-42.
12. Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005;23:8081-92.
13. Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol 2015;16:763-74.
14. Samakoglu S, Deevi DS, Li H, Wang S, Murphy M, Tonra JR, et al. Preclinical rationale for combining an EGFR antibody with cisplatin/ gemcitabine for the treatment of NSCLC. Cancer Genomics Proteomics 2012;9:77-92.
15. Sohye K, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Nat Acad Sci U S A 2005; 102:802-7.
16. Baselga J, CamponeM, Piccart M, Burris HA III, Rugo HS, Hortobagyi GN, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520.
17. Hortobagyi GN, Chen D2, Piccart M, Rugo HS, Burnstein HA, Baselga J, et al. Correlative analysis of genetic alterations and everolimus benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from BOLERO-2. J Clin Oncol 2016;34:419-26.
18. Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O'Reilly T, Lane HA, et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 2005; 11:5319-28.